News Quantified

SABS – sab biotherapeutics, inc. (US:NASDAQ)

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.

1/7

08:00 am

sabs

Medium

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}